# Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

> **NCT04911660** · PHASE2 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 50 (actual)

## Conditions studied

- Kidney Stone

## Interventions

- **DRUG:** Empagliflozin 25 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04911660
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-25
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-04-28
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911660, "Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04911660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*